normal1 The http://bit.ly/2tTA8fY" 14th Annual Call For Health Research Aids of the Mutua Madrileña Foundation has selected two research projects led by professionals from the Vall d'Hebron Barcelona Hospital Campus. In the area of rare diseases it has been selected the project that seeks to establish a personalized treatment for patients with cystic fibrosis and isled by Dr. Eduardo Tizzano, head of the http://bit.ly/2tZ3BWw" Genetic Medicine research group at Vall d'Hebron Research Institute (VHIR). Vall d'Hebron has also been selected in the field of transplantation and will lead a multicentre clinical trial to study markers of inflammation in lung donation and transplantation with Dr. Alberto Sandiumenge, member of the Transplant Coordination team at Vall d'Hebron and the lead researcher of CIBERES. normal1 In total, this organization has selected 18 works from various centres of the state, among which it will allocated a budget of 1.7 million euros. normal1 The projects, selected from over 140, are divided among the field of rare diseases, the area of transplants, oncology and traumatology. Each of them lasts between one and three years. The president of the Scientific Committee of the Foundation, Dr. Rafael Matesanz, said that with initiatives like this, "the aids not only contribute to scientific research, they have also saved hundreds of lives."Projects with the Vall d'Hebron seal normal1 In the area of rare diseases it has been selected the project led by Dr. Eduardo Tizzano, head of the http://bit.ly/2tZ3BWw" Genetic Medicine research group at Vall d'Hebron Research Institute (VHIR) and director of the http://bit.ly/2sUwrCu" Department of Clinical and Molecular Genetics of Vall Hebron. This project will attempt to establish a personalized treatment for patients with cystic fibrosis based on the functional analysis of specific mutations. The aim is to establish a prognosis of the patient response to different drugs correctors and powerups that can be used to treat the defective CFTR protein, to achieve accuracy or customized therapy and the optimization of health spending taking into account the economic impact of these treatments. normal1 Vall d'Hebron has also been selected in the field of transplantation. It will lead a multicentre clinical study, which involved most of the hospitals with a transplant program of the State to study inflammation markers in lung transplantation and donation. The study will compare the controlled donation in asystole and donation in brain death. normal1 One of the professionals who heads the project is Dr. Alberto Sandiumenge, member of the Transplant Coordination team at Vall d'Hebron and CIBERES researcher, who stressed the importance of the Mutua Madrileña Foundation's initiative. "To do research is not an easy task, even less in our context," he said. For this reason, "any help that facilitates the generation of stable resources that allow not only the scientific activity, but its sustainability, is necessary and welcome," always keeping in mind that "patients are the reason why and the motive of all scientific activity in the field of health".